Form 4: Vertex Pharmaceuticals Director Acquires Deferred Stock Units

Bruce I. Sachs, a director at Vertex Pharmaceuticals, acquired deferred stock units representing 95.475 shares of common stock on April 15, 2025.

Summary

• On April 15, 2025, Bruce I. Sachs, a director of Vertex Pharmaceuticals, acquired 95.475 deferred stock units.
• Each deferred stock unit represents one share of Vertex Pharmaceuticals common stock.
• The price per share was $497.51.
• These units will be paid out in common stock upon the earliest of Mr. Sachs' service termination on the board, a change of control of the company, or Mr. Sachs' disability or death.
• Following the transaction, Mr. Sachs beneficially owns 15,240.461 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard transaction by a company director. It doesn't inherently indicate positive or negative sentiment about the company's future.

Future Outlook

The deferred stock units will be paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, such as directors, offering insights into their confidence in the company's prospects.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider activity.

Key Dates

Keywords

Vertex Pharmaceuticals, Director, Deferred Stock Units, Beneficial Ownership, Form 4, VRTX, Equity Securities